Talphera Inc (TLPH)

$0.43 0.00 (N/A)
Market Cap 8.82M
Revenue (ttm) 0.00
Net Income (ttm) -13.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 208,900
Avg Vol 369,362
Day's Range N/A - N/A
Shares Out 20.50M
Stochastic %K 12%
Beta -0.11
Analysts Strong Sell
Price Target $3.25

Company Profile

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulation for direct IV infusion as an investigational product for various indications, such as antiviral,...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 650 216 3500
Address:
1850 Gateway Drive, Suite 175, San Mateo, United States
bobmoney
bobmoney Jul. 18 at 2:22 AM
$TLPH Standard of care... mandatory that an anticoagulant be used during Continual Renal Replacement Therapy...to prevent clotting of the Extracorporeal Circuit... - Heparin 3 hour half life causes systemic bleeding... etc. - Citrate used off label, which causes Calcium to be removed from the blood... etc. - Hint the need for Talphera's 8 minute half life anticoagulant Niyad, which works Safe & Effectively 30 years in Japan, South Korea... !!
0 · Reply
AlwaysRational
AlwaysRational Jul. 18 at 1:30 AM
$TLPH For months, the daily trading volume was basically nonexistent. After the big pump, we're still seeing much higher volume than usual, so something's up.
0 · Reply
bobmoney
bobmoney Jul. 17 at 11:00 PM
$TLPH Talphera's Niyad (FDA Breakthrough Designation) would be the -- only FDA approved anticoagulant for the Extracorporeal Circuit -- (Think kidneys... heart... lung) Talphera upon FDA Niyad approval: - 6 years FDA exclusivity protection... - Talphera also patents pending for 20 years exclusivity... !
0 · Reply
bobmoney
bobmoney Jul. 17 at 6:59 PM
$TLPH Volume... Bid to Buy high Volume block of shares went off at .4332... Bid showing 17,000 shares to Buy @ $.43... !
0 · Reply
bobmoney
bobmoney Jul. 17 at 6:46 PM
$TLPH yep, the games continue... if positive news any day, oh my... Would not bet against Talphera's new Chief Medical Officer... nephrologist doctor by training... & clinical research, drug and device safety and develooment successful background... !
0 · Reply
harvey4
harvey4 Jul. 17 at 6:17 PM
$TLPH Down every day. waiting for PR
0 · Reply
bobmoney
bobmoney Jul. 17 at 5:34 PM
$TLPH Monday 15 million shares... again, Talphera pending catalysts...any day! ...Talphera hit $.79 on million(s) of shares trading... ...large Short Seller million(s) of shares pressured shares lower... ...new Buyer(s) capitulated at 10% +/- stop loss triggers, pressured Shares lower... --- Short Interest is slowly covering at the expense of shares sold at a loss... !
0 · Reply
bobmoney
bobmoney Jul. 17 at 4:41 PM
$TLPH "...these patients have no other alternatives during Continual Renal Replacement Therapy..."
0 · Reply
bobmoney
bobmoney Jul. 17 at 4:39 PM
$TLPH May 14, 2025, -- Compassionate Use IDE -- Talphera's Chief Medical Officer "...Talphera is exploring, at the request of large medical institutions, Compassionate Use... physicians at these sites see an immediate and compelling need for their specific patients that don't do well with heparin or citrate..." !
0 · Reply
bobmoney
bobmoney Jul. 17 at 4:17 PM
$TLPH The new Phase 3 efficient ICU Medical clinical trial sites, and protocols, identified by Talphera's new Chief Medical Officer Shakil Aslam, MD (a nephrologist doctor by training)...
0 · Reply
Latest News on TLPH
Talphera, Inc. (TLPH) Q1 2025 Earnings Call Transcript

May 14, 2025, 9:01 PM EDT - 2 months ago

Talphera, Inc. (TLPH) Q1 2025 Earnings Call Transcript

Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:05 PM EDT - 2 months ago

Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025

May 7, 2025, 4:05 PM EDT - 2 months ago

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025

Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 6:33 PM EDT - 3 months ago

Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript

Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 31, 2025, 4:05 PM EDT - 3 months ago

Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million

Mar 31, 2025, 8:30 AM EDT - 3 months ago

Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million

Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025

Mar 26, 2025, 4:38 PM EDT - 4 months ago

Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025

Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study

Jan 14, 2025, 8:30 AM EST - 6 months ago

Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study

Talphera, Inc. (TLPH) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 6:43 PM EST - 8 months ago

Talphera, Inc. (TLPH) Q3 2024 Earnings Call Transcript

Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 4:05 PM EST - 8 months ago

Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024

Nov 6, 2024, 4:05 PM EST - 9 months ago

Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024

Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Oct 8, 2024, 4:54 PM EDT - 10 months ago

Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 4:15 PM EDT - 11 months ago

Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit

Aug 19, 2024, 8:30 AM EDT - 11 months ago

Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit

Talphera, Inc. (TLPH) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 6:39 PM EDT - 1 year ago

Talphera, Inc. (TLPH) Q2 2024 Earnings Call Transcript

Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024

Aug 5, 2024, 4:05 PM EDT - 1 year ago

Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024

Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 20, 2024, 5:25 PM EDT - 1 year ago

Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Talphera to Participate at A.G.P. Virtual Healthcare Conference

May 16, 2024, 5:45 PM EDT - 1 year ago

Talphera to Participate at A.G.P. Virtual Healthcare Conference

Talphera, Inc. (TLPH) Q1 2024 Earnings Call Transcript

May 14, 2024, 6:21 PM EDT - 1 year ago

Talphera, Inc. (TLPH) Q1 2024 Earnings Call Transcript

Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 14, 2024, 4:05 PM EDT - 1 year ago

Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update

Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024

May 2, 2024, 4:15 PM EDT - 1 year ago

Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024

Talphera, Inc. (TLPH) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 9:48 PM EST - 1 year ago

Talphera, Inc. (TLPH) Q4 2023 Earnings Call Transcript

Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update

Mar 6, 2024, 4:05 PM EST - 1 year ago

Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update

Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members

Mar 1, 2024, 7:30 AM EST - 1 year ago

Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members

Talphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024

Feb 26, 2024, 4:15 PM EST - 1 year ago

Talphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024

Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering

Jan 18, 2024, 8:30 AM EST - 1 year ago

Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering

bobmoney
bobmoney Jul. 18 at 2:22 AM
$TLPH Standard of care... mandatory that an anticoagulant be used during Continual Renal Replacement Therapy...to prevent clotting of the Extracorporeal Circuit... - Heparin 3 hour half life causes systemic bleeding... etc. - Citrate used off label, which causes Calcium to be removed from the blood... etc. - Hint the need for Talphera's 8 minute half life anticoagulant Niyad, which works Safe & Effectively 30 years in Japan, South Korea... !!
0 · Reply
AlwaysRational
AlwaysRational Jul. 18 at 1:30 AM
$TLPH For months, the daily trading volume was basically nonexistent. After the big pump, we're still seeing much higher volume than usual, so something's up.
0 · Reply
bobmoney
bobmoney Jul. 17 at 11:00 PM
$TLPH Talphera's Niyad (FDA Breakthrough Designation) would be the -- only FDA approved anticoagulant for the Extracorporeal Circuit -- (Think kidneys... heart... lung) Talphera upon FDA Niyad approval: - 6 years FDA exclusivity protection... - Talphera also patents pending for 20 years exclusivity... !
0 · Reply
bobmoney
bobmoney Jul. 17 at 6:59 PM
$TLPH Volume... Bid to Buy high Volume block of shares went off at .4332... Bid showing 17,000 shares to Buy @ $.43... !
0 · Reply
bobmoney
bobmoney Jul. 17 at 6:46 PM
$TLPH yep, the games continue... if positive news any day, oh my... Would not bet against Talphera's new Chief Medical Officer... nephrologist doctor by training... & clinical research, drug and device safety and develooment successful background... !
0 · Reply
harvey4
harvey4 Jul. 17 at 6:17 PM
$TLPH Down every day. waiting for PR
0 · Reply
bobmoney
bobmoney Jul. 17 at 5:34 PM
$TLPH Monday 15 million shares... again, Talphera pending catalysts...any day! ...Talphera hit $.79 on million(s) of shares trading... ...large Short Seller million(s) of shares pressured shares lower... ...new Buyer(s) capitulated at 10% +/- stop loss triggers, pressured Shares lower... --- Short Interest is slowly covering at the expense of shares sold at a loss... !
0 · Reply
bobmoney
bobmoney Jul. 17 at 4:41 PM
$TLPH "...these patients have no other alternatives during Continual Renal Replacement Therapy..."
0 · Reply
bobmoney
bobmoney Jul. 17 at 4:39 PM
$TLPH May 14, 2025, -- Compassionate Use IDE -- Talphera's Chief Medical Officer "...Talphera is exploring, at the request of large medical institutions, Compassionate Use... physicians at these sites see an immediate and compelling need for their specific patients that don't do well with heparin or citrate..." !
0 · Reply
bobmoney
bobmoney Jul. 17 at 4:17 PM
$TLPH The new Phase 3 efficient ICU Medical clinical trial sites, and protocols, identified by Talphera's new Chief Medical Officer Shakil Aslam, MD (a nephrologist doctor by training)...
0 · Reply
bobmoney
bobmoney Jul. 17 at 4:11 PM
$TLPH May 14, 2025 "...the new efficient clinical trial sites (ICU Medical Centers) lead by nephrologist(s) Primary Investigators... will allow us to complete the Phase 3 NEPHRO study by year-end..." !
0 · Reply
solua04
solua04 Jul. 17 at 2:31 PM
$TLPH The sentiment is bullish. But he stock price goes down, almost every day. How long to wait for progress or news?
0 · Reply
bobmoney
bobmoney Jul. 16 at 11:24 PM
$TLPH Talphera's Niyad (if FDA approved) annual Revenue estimated over -- $200 million dollars -- Now we wait on the Phase 3 NEPHRO clinical trial data... !!
0 · Reply
bobmoney
bobmoney Jul. 16 at 7:09 PM
$TLPH Phase 3 update... any time!
0 · Reply
harvey4
harvey4 Jul. 16 at 6:58 PM
$TLPH Is PR coming up ? accumulation is evident.
0 · Reply
bobmoney
bobmoney Jul. 16 at 6:47 PM
$TLPH now at the Bid of $.43 -- 98,400 shares to Buy -- !!
0 · Reply
bobmoney
bobmoney Jul. 16 at 6:18 PM
$TLPH 95,400 share Buy order hit the Bid of $.43... !!
0 · Reply
bobmoney
bobmoney Jul. 16 at 6:03 PM
$TLPH ok, so Talphera's current Market Cap = about $8 milllon dollars... Talphera estimates Niyad peak annual Revenue over -- $200 million dollars -- (assuming FDA approval, in late Phase 3 trials...). If I had an extra say $20 million sitting around, I would make a -- hostile takeover -- go private...post Niyad FDA approval go Public again at a likely $100 million plus Market Cap... !!!!
0 · Reply
bobmoney
bobmoney Jul. 16 at 5:47 PM
$TLPH Compassionate Use win for Talphera & the medical institutions would be a win for the kidney ill patients in need... !
0 · Reply
bobmoney
bobmoney Jul. 16 at 5:09 PM
$TLPH Re: Talphera's new Chief Medical Officer Shakil Aslam, MD... Dr. Aslam is a respected nephrologist, background in -- "...acute and chronic kidney diseases, hypertension, and other kidney diseases..." - & Dr. Aslam 20 years experience in "...clinical research and drug and device safety and development." Positive for the Talphera NEPHRO Phase 3 clinical trial underway... !
0 · Reply
PicassoGalileo
PicassoGalileo Jul. 16 at 3:22 PM
$NUWE All profits to $TLPH
0 · Reply
PicassoGalileo
PicassoGalileo Jul. 16 at 3:21 PM
$APM Next $TLPH
0 · Reply